摘要
尽管有关的发病机制和新的治疗策略的最新研究发现,在急性肾损伤(AKI)患者的死亡率仍然很高。有肾功能损害的早期检测的患者可能有助于确保更积极的治疗,提高临床疗效。血清肌酐仍然是肾损伤的金标准,虽然它被称为不敏感和不可靠的生物标志物(例如,它的浓度不增加显着,直到约一半的肾功能丢失)。考虑到这些数据,研究和临床医生都作出了巨大的努力,在过去的十年里,为了发现和验证新的AKI生物标志物。肾损伤分子-1(KIM-1)、中性粒细胞明胶酶蛋白(NGAL)、白细胞介素-18(IL-18)、Cystatin C(Cys-C)有一些新的肾损伤,目前在临床前和临床研究的重点有前途的标记。最近的数据表明,这些新的生物标志物,是急性肾小管坏死的重要参数(ATN)和预后的可靠预测AKI的发展。此外,这些标志物的监测可以早期诊断和临床过程有重要意义,不仅在各种形式的AKI和其他肾脏疾病的患者,而且患者心肾综合征、心力衰竭、心肺转流,心胸外科干预,在儿科急救设置等有作用。 这篇评论的目的是总结一些新的生物标志物的文献资料,评估他们的作用,以及他们的局限性,在早期诊断和预测一些肾脏疾病的临床结果。
关键词: 急性肾损伤(AKI)的新型生物标志物,肾,肾损伤分子(KIM-1)、中性粒细胞明胶酶相关脂质运载蛋白(NGAL)、白细胞介素-18(IL-18)、胱抑素C(Cys-C)。
Current Medicinal Chemistry
Title:Evaluation of Novel Biomarkers of Acute Kidney Injury: The Possibilities and Limitations
Volume: 23 Issue: 19
Author(s): Branislava Medić, Branislav Rovcanin, Katarina Savic Vujovic, Danilo Obradovic, Dusan Duric, Milica Prostran
Affiliation:
关键词: 急性肾损伤(AKI)的新型生物标志物,肾,肾损伤分子(KIM-1)、中性粒细胞明胶酶相关脂质运载蛋白(NGAL)、白细胞介素-18(IL-18)、胱抑素C(Cys-C)。
摘要: Despite the recent findings concerning pathogenesis and novel therapeutic strategies, the mortality rate in patients with acute kidney injury (AKI) remains very high. Early detection of patients with impaired renal function may help to ensure more aggresive treatment and to improve clinical outcome. Serum creatinine is still gold standard of kidney injury, although it is well known as an insensitive and unreliable biomarker (for example, its concentration does not increase significantly until about half of the kidney function is lost). Considering these data, researches and clinicians are making great efforts in the past decade in order to discover and validate novel AKI biomarkers. Kidney injury molecule-1 (KIM-1), Neutrophil gelatinase-associated lipocalin (NGAL), Interleukin-18 (IL-18), Cystatin C (Cys-C) are some of new, promising markers of kidney damage which are currently in the focus of preclinical and clinical studies. Recent data suggest that some of these new biomarkers represent important parametars of acute tubular necrosis (ATN) and reliable predictors of development and prognosis of AKI. Beside that, monitoring of these markers could have significant importance for early diagnosis and clinical course, not only in patients with various forms of AKI and other renal diseases, but also in patients with cardiorenal syndrome, heart failure, cardiopulmonary bypass, cardiothoracical surgical interventions, in the pediatric emergency setting etc.
The aim of this review is to summarize the literature data concerning some new biomarkers, evaluate their role as well as their limitations in the early diagnosis and predict clinical outcome of some renal diseases.
Export Options
About this article
Cite this article as:
Branislava Medić, Branislav Rovcanin, Katarina Savic Vujovic, Danilo Obradovic, Dusan Duric, Milica Prostran , Evaluation of Novel Biomarkers of Acute Kidney Injury: The Possibilities and Limitations, Current Medicinal Chemistry 2016; 23 (19) . https://dx.doi.org/10.2174/0929867323666160210130256
DOI https://dx.doi.org/10.2174/0929867323666160210130256 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Activation of Sphingosine Kinase-1 in Cancer: Implications for Therapeutic Targeting
Current Molecular Pharmacology Current Therapeutic Drugs Against Cerebral Vasospasm after Subarachnoid Hemorrhage: A Comprehensive Review of Basic and Clinical Studies
Current Drug Delivery Resident and Non-Resident Stem Cells in Acute Myocardial Infarction
Cardiovascular & Hematological Disorders-Drug Targets Clinical Significance of the Sympathetic Nervous System in the Development and Progression of Pulmonary Arterial Hypertension
Current Neurovascular Research The Chemical Biology of Immunophilin Ligands
Current Medicinal Chemistry Thromboprophylaxis in Medical Patients: An Update
Vascular Disease Prevention (Discontinued) Thiazide Diuretics: 50 Years and Beyond
Current Hypertension Reviews Sestrins: A New Kid for Stroke Treatment?
Current Drug Delivery Stem Cell Implantation for Myocardial Disorders
Current Drug Delivery Diabetes as a Negative Risk Factor for Abdominal Aortic Aneurysm – Does the Disease Aetiology or the Treatment Provide the Mechanism of Protection?
Current Vascular Pharmacology Exercise Rehabilitation for the Patient with Intermittent Claudication: A highly Effective yet Underutilized Treatment
Current Drug Targets - Cardiovascular & Hematological Disorders Clinical Vignettes: Integrated Care of Cancer Patients by Oncologists and Cardiologists
Current Cardiology Reviews Cytotoxic Properties of Clofibrate and other Peroxisome Proliferators: Relevance to Cancer Progression
Current Medicinal Chemistry Novel Trends in the Treatment of Cardiovascular Disorders: Site- and Event- Selective Adenosinergic Drugs
Current Medicinal Chemistry Living Life to the Fullest: Early Integration of Palliative Care into the Lives of Children with Chronic Complex Conditions
Current Pediatric Reviews Fatty Acid Amide Hydrolase: A Potential Target for Next Generation Therapeutics
Current Pharmaceutical Design Overexpression of a Modified Amaranth Protein in Escherichia coli with Minimal Media and Lactose as Inducer
Recent Patents on Biotechnology Therapeutic Targets for the Management of Peripheral Nerve Injury- Induced Neuropathic Pain
CNS & Neurological Disorders - Drug Targets Ziconotide Monotherapy: A Systematic Review of Randomised Controlled Trials
Current Neuropharmacology The Role of Vitamin D in Dyslipidemia and Cardiovascular Disease
Current Pharmaceutical Design